

Inside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Sacituzumab tirumotecan targets which of the following antigens?**
 - a. B7-H3
 - b. HER2
 - c. HER3
 - d. TROP2**
- 2. Interim analysis of the MORPHEUS-panBC study reported encouraging activity with the combination of sacituzumab govitecan and atezolizumab in which line of therapy for patients with PD-L1-positive locally advanced or metastatic triple-negative breast cancer?**
 - a. First line**
 - b. Second line
 - c. Later line
- 3. HER2-low metastatic breast cancer is more commonly which of the following subtypes?**
 - a. ER-negative
 - b. ER-positive**
 - c. Low HER2 expression is equally common in ER-negative and ER-positive disease
- 4. Which of the following best describes the efficacy of trastuzumab deruxtecan (T-DXd) in patients with advanced HER2-low breast cancer in the Phase III DESTINY-Breast04 trial?**
 - a. Benefit was significantly greater in the IHC 1+ population
 - b. Benefit was significantly greater in the IHC 2+ population
 - c. Benefit was similar in the IHC 1+ and IHC 2+ populations**
- 5. The Phase III DESTINY-Breast06 trial is evaluating T-DXd versus chemotherapy for patients with metastatic hormone receptor-positive breast cancer and which HER2 subtype?**
 - a. HER2-positive
 - b. HER2-low
 - c. HER2 ultra-low
 - d. Both HER2-positive and HER2-low
 - e. Both HER2-low and HER2-ultralow**